Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: BSX.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Boston Scientific (BSX) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

STRONG BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

STRONG BUY

$53

+21.4%

2031

5-Year

STRONG BUY

$97

+123.1%

Published batch insight

Procedural Moats and Vascular Scale Drive Cash Recovery Beyond Disruption

Sharp divergence characterizes market sentiment between short-term electrophysiology share losses post-cyberattack and enduring procedural cash flows. High consensus affirms that non-discretionary cardiovascular demand and the Penumbra integration support cash-flow recovery, while competitive catheter pricing and elevated acquisition leverage remain primary structural frictions.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Michael Burry (Vulture), J.P. Morgan (Titan), Universal Investor (Polymath), Superintelligence (Anthropologist), Machiavelli (Insider), Elon Musk (Visionary), Warren Buffett (Value Purist), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Boston Scientific at the forecast anchor (2026-09-18): $22,312 in five years versus $13,892 for S&P 500 benchmark.

Boston Scientific · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Boston Scientific compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 43.34 USD1-year price return: +21.44%5-year price return: +123.12%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	44.93	+3.66%	+3.66%	Third-quarter financial disclosures reveal cyber disruption remediation costs and delayed shipments, offset by baseline procedure resilience. Investors establish an initial valuation floor as supply-chain restoration commences and Penumbra merger financing terms gain clarity.
Q1 2027	47.71	+6.20%	+10.09%	Fourth-quarter results show aggressive order catch-up, clearing deferred catheter backlogs. Conservative full-year guidance confirms 2027 as a foundational transition year, relieving catastrophic fears and encouraging institutional accumulation from trough multiples.
Q2 2027	50.25	+5.33%	+15.95%	Penumbra acquisition closes, expanding peripheral thrombectomy procedural scale. Cross-selling synergies across international cath labs begin materializing, cushioning near-term debt service expenses and initial electrophysiology pricing competition from rival platforms.
Q3 2027	52.63	+4.73%	+21.44%	Initial operational restructuring efficiencies generate overhead savings, stabilizing operating margins above 20%. Sustained procedure volumes across endoscopy and interventional cardiology counterbalance competitive pricing pressure in domestic pulsed-field ablation accounts.
Q4 2027	55.48	+5.42%	+28.02%	Year-end procedural volume catch-up accelerates operating cash flows. Management directs surplus liquidity toward initial debt retirement, easing credit spread concerns and supporting modest equity multiple recovery as structural heart referrals stabilize.
Q1 2028	58.55	+5.53%	+35.10%	Commercial rollout of next-generation electrophysiology catheters and intravascular lithotripsy commences. Demonstrable clinical workflow improvements stem domestic market share losses, prompting positive earnings revisions across institutional research models.
Q2 2028	61.50	+5.03%	+41.90%	Accelerating thrombectomy adoption across European and Asian hospitals drives accretive top-line contribution. Expanding manufacturing automation defends consolidated gross margins, enabling consistent free-cash-flow conversion despite elevated sovereign bond yields.
Q3 2028	63.55	+3.34%	+46.64%	Cyclical hospital procurement reviews and competitive ablation bundling introduce temporary average selling price friction. However, non-discretionary procedure volumes across core cardiovascular lines cushion consolidated revenue, limiting valuation pullbacks.
Q4 2028	66.64	+4.86%	+53.76%	Full-year free cash flow surpasses $4.2 billion, validating post-merger cash generation. Deleveraging milestone targets are achieved ahead of schedule, reducing financial risk discounts and encouraging steady long-term institutional accumulation.
Q1 2029	69.67	+4.55%	+60.76%	Enterprise restructuring program delivers over half of targeted $500 million run-rate savings. Operating leverage widens operating margins, driving high-single-digit per-share earnings growth that offsets higher debt refinancing coupons.
Q2 2029	72.43	+3.96%	+67.12%	International commercial penetration in Japan and emerging markets delivers double-digit procedural expansion. Broader procedural diversification insulates the franchise from mature domestic catheter price competition, supporting sustained equity compounding.
Q3 2029	75.22	+3.85%	+73.56%	Thrombectomy cross-selling maturity and advanced imaging integration enhance hospital account retention. Incremental operating efficiencies drop directly to free cash flow, sustaining positive equity momentum through defensive medical device demand.
Q4 2029	78.15	+3.90%	+80.33%	Full achievement of enterprise restructuring savings expands normalized operating margins past 22%. Net debt to EBITDA approaches normalized targets, enabling management to reactivate disciplined share repurchases.
Q1 2030	81.16	+3.85%	+87.27%	Audited fiscal results demonstrate robust return on invested capital and durable cash conversion. Reduced share count and lower interest expense amplify per-share earnings growth, reinforcing multi-year multiple normalization.
Q2 2030	83.70	+3.13%	+93.13%	Mature clinical adoption across pulsed-field ablation and left-atrial-appendage closure yields highly predictable consumable reorder streams. Consistent cash collection insulates operating returns from broader late-cycle macroeconomic deceleration.
Q3 2030	85.65	+2.32%	+97.61%	Hospital procurement committees tighten capital budgets, moderately dampening new console placements. Resilient single-use disposable catheter utilization protects operating income, preserving steady baseline cash flows despite modest multiple compression.
Q4 2030	88.63	+3.49%	+104.51%	Seasonal elective procedural catch-up and disciplined operating expense controls drive strong fourth-quarter cash generation. Surplus free cash flow fuels continued debt reduction, cementing an investment-grade balance sheet profile.
Q1 2031	91.44	+3.16%	+110.97%	Annual guidance confirms a diversified, high-cash-flow medical technology leader compounding at mid-single digits organically. Consistent operating margin resilience above 22% supports fair valuation multiples reflective of high-barrier medtech peers.
Q2 2031	94.10	+2.92%	+117.13%	Next-generation peripheral vascular and structural heart pipelines enter clinical deployment, defending category relevance. Expanding international procedural volumes offset mature domestic market growth, maintaining dependable top-line momentum.
Q3 2031	96.70	+2.76%	+123.12%	The five-year recovery arc concludes with normalized operating earnings and strong cash yields fully established. Valuation settles around historical medtech medians, delivering substantial total shareholder return from 2026 trough capitulation.

The investment case balances an acute valuation contraction against the underlying compounding power of an essential medical device portfolio. Following successive guidance cuts and temporary cyber disruption, market pricing discounts permanent impairment across electrophysiology and left-atrial-appendage franchises. However, approximately 75% of operations continue compounding organically near 6%, supported by $3.62 billion in trailing free cash flow. Integrating Penumbra secures vascular thrombectomy leadership, while a $500 million restructuring program defenses operating margins toward 22%. Valuation sensitivity centers on post-acquisition balance sheet absorption. Deploying $11 billion in new debt into a 5% sovereign yield curve elevates interest expense, restricting capital returns and near-term multiple re-expansion. The strongest counterargument highlights irreversible pulsed-field ablation share losses to well-capitalized conglomerates.

Key insights

Secular demographic volume growth in cardiovascular procedures provides non-discretionary demand that permanently decouples operational cash flows from broader macroeconomic interest-rate volatility.
Penumbra platform consolidation diversifies procedural exposure away from contested cardiac lines, establishing high-margin clinical chokepoints across neurovascular and peripheral interventions.
Post-merger deleveraging and structural restructuring capture will drive per-share owner earnings growth far faster than headline top-line expansion implies.

Deep Dive

Prevailing market sentiment treats the enterprise as a fallen growth story whose competitive advantage has evaporated. Analysts focus on decelerating electrophysiology momentum, intensifying competition from conglomerates, standalone Watchman referral plateaus, and cyberattack disruptions. The crowd assumes high-growth compounding is finished, pricing the equity at a trough multiple of 17.5 times trailing earnings.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd materially underestimates intrinsic value, causing severe underpricing. The market mistakenly conflates temporary cyber disruptions and category normalization in two specific franchises with permanent corporate impairment. It overlooks that 75% of revenues compound steadily at 6% with 70% gross margins, supported by $3.62 billion in free cash flow. The strongest challenge is sustained catheter price competition, yet non-discretionary procedural volume creates an unpriced margin of safety.

Repricing catalyst

A sequence of clean financial prints demonstrating normalized order shipping and stabilizing electrophysiology market share through early 2027 will shatter the broken-growth narrative. Repricing will gain decisive momentum as Penumbra thrombectomy sales consolidate, proving that procedural backlogs were deferred rather than permanently lost and forcing sell-side earnings revisions.

Published consensus context

Macro regime alignment

The macroeconomic regime of 3.75% to 4.00% policy rates and 5% Treasury yields creates moderate headwinds for hospital capital budgets and acquisition debt service. However, non-discretionary cardiovascular demand exhibits low economic sensitivity, enabling 70% gross margins and $3.6 billion in cash flow to outpace medical inflation.

Published consensus context

Advisor disagreement

The decisive disagreement centers on the durability of electrophysiology growth and the valuation multiple applied to normalized cash flows. Bullish analyses argue that Farapulse retains an unassailable clinical moat and model swift multiple re-expansion to 24x earnings as next-generation catheters launch. Conversely, cautious perspectives demonstrate that rival pulsed-field ablation platforms are causing irreversible market-share dilution, while $11 billion in acquisition debt will constrain per-share earnings growth. Observing whether domestic electrophysiology sales stabilize above 6% organic growth across upcoming quarterly prints will determine whether the thesis becomes an earnings compounder or a valuation-capped recovery.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Penumbra Vascular Platform Absorption: Integrating Penumbra's market-leading mechanical thrombectomy and neurovascular portfolios injects a scaled, high-margin growth engine. Cross-selling through global commercial channels captures hospital cath-lab call points, adding over $1.5 billion in accretive cardiovascular revenue and expanding enterprise procedural breadth over the forecast horizon. Expected impact: +28%.
Non-Electrophysiology Franchise Compounding: Three-quarters of the portfolio outside electrophysiology—including Interventional Cardiology, Endoscopy, and Urology—continues compounding organically at 6% to 7%. Underwritten by non-discretionary clinical demand, this diversified base reliably generates over $3.6 billion in free cash flow, anchoring corporate earning power. Expected impact: +24%.
Next-Generation Catheter Innovation Cycle: Launching next-generation pulsed-field ablation catheters, integrated intracardiac echocardiography, and intravascular lithotripsy counters competing entrants. Enhanced procedural efficiency and clinical workflow integration defend catheter realization rates, stabilizing electrophysiology division revenue growth above high single digits through mid-term adoption. Expected impact: +22%.
Enterprise Operational Restructuring Harvest: A multi-year operational efficiency initiative targets $500 million in structural annualized cost savings by exiting 2029, with over half captured by 2027. Streamlining global administrative overhead and automating precision manufacturing expands operating margins toward 22%, directly compounding per-share owner cash flows. Expected impact: +18%.

Top frictions and headwinds

Intensifying Pulsed-Field Catheter Competition: Aggressive commercial rollouts of competing pulsed-field ablation catheters by Medtronic and Johnson & Johnson erode early monopoly market share toward 50%. Multi-vendor hospital purchasing contracts force price concessions on mapping and catheters, permanently compressing division growth from historical peaks. Expected impact: -18%.
Acquisition Leverage Financing Drag: Funding the $14.5 billion Penumbra transaction requires approximately $11 billion in new borrowing amid 5% Treasury yields, adding substantial annual interest expense. Elevated debt service absorbs operating cash flows, restricting near-term discretionary share repurchases until balance sheet deleveraging targets are achieved. Expected impact: -14%.
Structural Heart Referral Deceleration: Standalone left-atrial-appendage closure growth decelerated to single digits as cardiologists adjust referral criteria toward concomitant procedures following recent trial interpretations. Slower volume expansion across high-margin Watchman implants removes a primary historical growth engine, capping corporate gross margin expansion. Expected impact: -12%.
Hospital Procurement Budget Constraints: Elevated healthcare labor costs and restrictive reimbursement updates squeeze hospital operating margins globally. Value-based procurement committees scrutinize premium medical device pricing and lengthen capital equipment purchasing cycles, moderating console placement velocity and single-use catheter reorder momentum. Expected impact: -9%.

Tail risks

Catastrophic Electrophysiology Safety Recall: An unexpected post-market clinical safety signal or severe tissue complication involving pulsed-field ablation catheters could prompt urgent FDA warning letters or commercial holds by 2027. Halting catheter shipments would forfeit market leadership to waiting competitors, trigger material litigation liabilities, and eliminate hundreds of millions in operating profit. Probability: +18%. Expected impact: -32%.
Antitrust Injunction Against Penumbra: Antitrust litigation by the Federal Trade Commission or European regulators challenging the $14.5 billion Penumbra transaction on vascular monopoly grounds could block the acquisition in late 2026. Deal termination would trigger heavy breakup fees, forfeiting entry into mechanical thrombectomy and stranding capital allocation strategy. Probability: +20%. Expected impact: -20%.

Tail opportunities

CHAMPION First-Line Indication Approval: Extended clinical trial readouts establishing Watchman FLX superiority over direct oral anticoagulants in broad non-valvular atrial fibrillation cohorts could trigger FDA first-line label expansion by 2028. Moving from secondary contraindication therapy to primary prevention would quadruple the addressable patient population, injecting over $1 billion in high-margin revenue. Probability: +32%. Expected impact: +32%.
Accelerated Thrombectomy Synergies Realization: Consolidating Penumbra's computer-assisted vacuum thrombectomy platforms through established multinational distribution channels could outpace modeled cross-selling projections by 30%. Rapid procedural adoption across European and Asian surgical centers by 2028 would generate substantial unexpected operating income, accelerating corporate debt retirement and multiple rerating. Probability: +28%. Expected impact: +24%.

What to monitor

Thesis watchpoints

-- Confirmation: Organic revenue growth across non-electrophysiology franchises holding at or above 6.0% through mid-2027 confirms broad portfolio insulation.

Key insights

Deterioration: Sequential U.S. electrophysiology revenue declining for two consecutive reported quarters by September 2027 signals deep structural share loss.
Reassessment: Net debt exceeding 3.5 times adjusted EBITDA post-merger closing requires an immediate review of capital allocation priorities.

Company Financial Analysis

Boston Scientific Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Boston Scientific delivered strong revenue of $20.1 billion in fiscal 2025, surging nearly 20% year-over-year as its pioneering heart ablation systems gained rapid global adoption. However, growth slowed to 7.5% in the second quarter of 2026 as competing device makers launched rival systems and an August computer outage briefly disrupted factory shipments. This headline slowdown led management to trim full-year organic growth guidance to around 5% to 6%. Crucially, this deceleration represents a transition toward steady cash generation rather than corporate decay. Trailing twelve-month free cash flow reached a formidable $3.62 billion, proving that patient care generates dependable cash regardless of quarterly noise. Because scheduled cardiovascular procedures are deferred rather than canceled, cleared shipping backlogs will restore recognized earnings into 2027.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 20.1B	USD 2.9B	USD 3.7B
2024	USD 16.7B	USD 1.9B	USD 2.6B
2023	USD 14.2B	USD 1.6B	USD 1.7B
2022	USD 12.7B	USD 698M	USD 914M
2021	USD 11.9B	USD 1B	USD 1.3B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	49.4x	TTM	Native	USD / USD
2024	71.8x	TTM	Native	USD / USD
2023	53.6x	TTM	Native	USD / USD
2022	95.6x	Annual	Native	USD / USD
2021	58.7x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profit margins widened significantly in fiscal 2025, with gross margins climbing to 69% and operating margins reaching nearly 20%. This profitability surge occurred because premium heart implants and specialty catheters carry strong pricing power and cost very little to produce once manufacturing reaches scale. High-margin procedure volume dropped directly to the bottom line. While competitor discounting in electrophysiology and temporary cyber recovery expenses will flatten near-term margins, long-term profitability remains well protected. An enterprise restructuring plan targeting $500 million in annual overhead savings by 2029 will counterbalance pricing pressures. As higher-margin vascular products integrate into global sales channels, operating margins should sustainably stabilize above 22%. over time.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 4B	19.8%	14.4%
2024	USD 2.6B	15.7%	11.1%
2023	USD 2.2B	15.3%	11.2%
2022	USD 1.8B	14.4%	5.5%
2021	USD 1.9B	16.2%	8.7%

Balance sheet and leverage

AI Review

The company entered 2026 with a solid financial foundation, supported by $24.2 billion in shareholder equity and a low debt-to-equity ratio of 0.51. Operating earnings covered annual interest payments more than ten times over, providing absolute protection against everyday financial turbulence. Strong cash generation gives the company substantial flexibility to navigate volatile market environments. The critical test ahead involves absorbing the pending $14.5 billion Penumbra purchase, which requires approximately $11 billion in new borrowing. While this debt will temporarily increase balance sheet leverage during a period of higher interest rates, more than $3.6 billion in annual free cash flow provides sufficient firepower to pay down debt rapidly without threatening financial stability.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 12.4B	USD 2B	USD 10.4B net debt	1.62x
2024	USD 11.1B	USD 414M	USD 10.7B net debt	1.08x
2023	USD 9.5B	USD 865M	USD 8.6B net debt	1.32x
2022	USD 9.3B	USD 928M	USD 8.4B net debt	1.51x
2021	USD 9.5B	USD 1.9B	USD 7.5B net debt	1.48x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management maintains a disciplined capital footprint, spending just 4.4% of revenue on physical buildings and factory equipment in fiscal 2025. Instead of constructing expensive real estate, the company directs capital toward product engineering and clinical trials, investing over $2.05 billion directly into research and development. This focused spending protects high-margin product designs and automates cleanroom catheter assembly. The real investment story lies in strategic acquisitions. Committing $14.5 billion for Penumbra and $1.5 billion for heart valve specialist MiRus allows the business to buy proven, fast-growing medical technologies rather than building them from scratch. This strategy commits substantial upfront capital but quickly opens major new hospital markets.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 876M	USD 2.1B
2024	USD 790M	USD 1.6B
2023	USD 800M	USD 1.4B
2022	USD 612M	USD 1.3B
2021	USD 554M	USD 1.2B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	STRONG_BUY	410	+22.6%	Not available	ORIGINAL
5Y	STRONG_BUY	347	+131%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	39.87	45.26	48.11	14
+6M	March 18, 2027	43.06	48.11	51.96	14
+9M	June 18, 2027	45.03	50.66	55.07	14
+1Y	September 18, 2027	45.93	53.13	57.33	14
+15M	December 18, 2027	47.77	56.11	60.19	14
+18M	March 18, 2028	50.16	59.29	64.42	14
+21M	June 18, 2028	52.17	62.33	68.93	14
+2Y	September 18, 2028	52.7	64.8	73.06	14
+27M	December 18, 2028	55.33	67.98	77.45	14
+30M	March 18, 2029	57.54	71.16	81.32	14
+33M	June 18, 2029	59.84	74.04	85.38	14
+3Y	September 18, 2029	61.06	77.05	89.65	14
+39M	December 18, 2029	62.89	80.06	93.24	14
+42M	March 18, 2030	64.77	83.3	97.88	14
+45M	June 18, 2030	66.07	85.96	101.8	14
+4Y	September 18, 2030	65.29	88.5	105.87	14
+51M	December 18, 2030	67.9	91.55	110.11	14
+54M	March 18, 2031	69.94	94.62	115.61	14
+57M	June 18, 2031	72.04	97.41	119.08	14
+5Y	September 18, 2031	73.66	100.12	122.65	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The independently supported consensus pattern confirms that approximately 75% of operations outside electrophysiology and structural heart continue compounding steadily at 6% to 7% organically, generating over $3.6 billion in trailing free cash flow. Correlated assumptions across bullish reports inappropriately extrapolate rapid valuation rerating back to 25x earnings while understating the friction of funding the $14.5 billion Penumbra transaction in a 5% interest-rate regime. The strongest contrarian case establishes that electrophysiology market share erosion from rival pulsed-field ablation entrants and slowed standalone left-atrial-appendage referrals represent permanent structural adjustments rather than temporary blips. Unsupported claims regarding frictionless commercial synergy and immediate multiple recovery were heavily downweighted. Unresolved uncertainties include post-cyberattack customer retention, final antitrust closing conditions, and integration leverage. These findings assign primary weight to rigorously documented, cash-flow-grounded reports that model deliberate margin recovery while penalizing unevidenced multiple expansion.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight12.0/100

This analysis provides exceptional primary evidence regarding post-cyber recovery filings, SEC disclosures, and conservative capital constraints. Its cautious cash-flow compounding scenario captures realistic margin pressures and Penumbra debt friction without overstating immediate multiple expansion, offering sound causal consistency and independent analytical balance.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight10.0/100

Strong macroeconomic grounding and thorough appraisal of the non-electrophysiology portfolio justify this allocation. The report accurately evaluates the 5% Treasury yield backdrop, debt service requirements for Penumbra, and realistic operational restructuring timelines, presenting a balanced and causal long-term pathway.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight9.0/100

Featuring detailed evidentiary sourcing on cyberattack resolution and FDA access-system corrections, this report provides deep operational clarity. It accurately balances steady compounding across 75% of operations against realistic electrophysiology share loss and Penumbra integration burdens.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight8.0/100

This viewpoint offers rigorous forensic skepticism, correctly identifying deferred versus destroyed procedural revenues post-cyberattack and parsing pro-forma leverage risks. Its prudent multiple expansion assumptions and emphasis on cash conversion yield a well-reasoned contrarian margin of safety.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight8.0/100

Grounding its view in durable owner earnings and capital discipline, this report effectively analyzes the 5.6% free-cash-flow yield and share retirements. It balances competitive ablation erosion against broad-based interventional compounding, providing high causal consistency and disciplined valuation metrics.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight8.0/100

This submission offers a well-documented analysis of the 2026 guidance cuts, enterprise restructuring initiatives, and upcoming 2027 product launches. Its thesis logically bridges short-term operational capitulation to mid-term cash-flow normalization, supported by solid financial evidence.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight8.0/100

With exhaustive primary documentation on SEC filings, Class I recall corrections, and antitrust timelines, this perspective provides exceptional factual grounding. Its sober recognition of guidance credibility deficits and realistic 15x exit valuation anchors the consensus path.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight7.0/100

The evaluation details institutional hospital inertia, CMS inpatient reimbursement moats, and operational restructuring savings effectively. However, it underweights post-acquisition leverage under restrictive monetary policy and assumes swift multiple expansion, meriting a moderate weight reflecting solid regulatory and commercial insights.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight6.0/100

This thesis presents compelling demographic framing and procedural stickiness arguments but suffers from philosophical abstraction rather than detailed balance sheet scrutiny. It underestimates acquisition financing friction and competitive catheter pricing dynamics, justifying a modest weighting grounded in structural procedural demand.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight6.0/100

The report highlights technological paradigm shifts in pulsed-field ablation and procedural velocity, but relies on overly rapid multiple recovery assumptions. It downplays prolonged customer contract friction and antitrust review risk, warranting a measured allocation focused on technological hardware moats.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight6.0/100

The assessment demonstrates sound understanding of clinical training inertia, high switching costs, and non-deferrable procedure volumes. However, it projects optimistic operating margin expansion without fully penalizing the capital allocation drag of pending merger debt, warranting a moderate weight.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight5.0/100

The perspective relies heavily on aggressive operational turnaround assumptions, projecting rapid margin expansion to 25x earnings while dismissing intense pulsed-field ablation competition. While vascular cross-selling arguments are directionally viable, lack of citation rigor and excessive near-term optimism limit its overall portfolio weighting.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight5.0/100

While correctly identifying inelastic clinical demand and strong underlying gross margins, the analysis minimizes credible multi-source pulsed-field ablation competition from large conglomerates. Its aggressive multiple rerating scenario lacks grounding in near-term cash deployment realities, warranting a lower allocation.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight2.0/100

While correctly identifying structural heart clinical durability, the report largely ignores the multi-billion-dollar financing and integration headwinds of the Penumbra acquisition. Its assumption of rapid, frictionless multiple rerating without addressing debt drag warrants a minimal weighting.

Skip to references

Research Provenance

References & Context

This Boston Scientific consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 116 deduplicated sources retained for this batch.

01Vascular Access Systems Correction: Boston Scientific Updates Use Instructions for WATCHMAN Access Systems | FDAfda.gov
02BOSTON SCIENTIFIC CORP - Form 425 - FY2026sec.gov
03BOSTON SCIENTIFIC CORP - Form 8-K - FY2026sec.gov
04bsx-20260907sec.gov
05https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/q22026earningsrelease.htm?utm_source=openaisec.gov
06FDA issues most serious recall for certain pacemaker devices by Boston Scientific | AHA Newsaha.org
07Boston Scientific (BSX) Q2 2026 Earnings Call Transcript - AOLaol.com
08Understand the CHAMPION-AF LAAC vs NOACs trial results - Boston Scientificbostonscientific.com
09Boston Scientific to acquire Penumbra for $14.5Bcardiovascularbusiness.com
10Steerable sheaths for PFA recalled due to safety riskcardiovascularbusiness.com
11BSX Stock Quote Price and Forecast | CNNcnn.com
12Boston Scientific cuts guidance again after unveiling restructuring planfiercebiotech.com
13Boston Scientific again cuts 2026 guidancefinance.yahoo.com
14Boston Scientific Corporation (BSX) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
15Boston Scientific trims annual profit forecast on softer Watchman device demand By Reutersinvesting.com

And 101 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.